Compare OPK & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | DBVT |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 948.8M |
| IPO Year | 2011 | 2014 |
| Metric | OPK | DBVT |
|---|---|---|
| Price | $1.24 | $13.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $1.60 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 2.8M | 251.2K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $606,879,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | $4.24 | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $0.98 | $8.51 |
| 52 Week High | $1.61 | $26.19 |
| Indicator | OPK | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 34.34 |
| Support Level | $1.11 | $12.63 |
| Resistance Level | $1.25 | $14.68 |
| Average True Range (ATR) | 0.06 | 0.80 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 16.92 | 14.73 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.